XML 29 R22.htm IDEA: XBRL DOCUMENT v3.24.3
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

13. Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the three and nine months ended September 30, 2024 and 2023, respectively (in thousands, except share and per share amounts):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Net loss attributable to Adaptive Biotechnologies Corporation

 

$

(32,071

)

 

$

(50,300

)

 

$

(125,800

)

 

$

(155,809

)

Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

 

147,516,398

 

 

 

144,704,868

 

 

 

146,908,234

 

 

 

144,208,940

 

Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

 

$

(0.22

)

 

$

(0.35

)

 

$

(0.86

)

 

$

(1.08

)

Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive.

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three and nine months ended September 30, 2024 and 2023, respectively, as they had an anti-dilutive effect:

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Stock options outstanding

 

 

12,520,579

 

 

 

13,806,283

 

 

 

12,885,829

 

 

 

14,054,478

 

Nonvested restricted stock units outstanding

 

 

10,578,591

 

 

 

10,301,308

 

 

 

10,697,694

 

 

 

9,575,868

 

Maximum nonvested market-based restricted stock units outstanding eligible to be earned

 

 

3,831,114

 

 

 

1,912,674

 

 

 

3,385,117

 

 

 

1,580,146

 

Total

 

 

26,930,284

 

 

 

26,020,265

 

 

 

26,968,640

 

 

 

25,210,492